# US 6,294,581 B1 · Inhibition of IgA production

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,294,581 B1
- Document ID: US6294581B1
- Status: Granted
- Kind: B1
- Application number: 09/646,350
- Filed: 2000-09-18
- Granted: 2001-09-25
- Earliest claimed: 1998-05-15
- Assignees: Takara Shuzo Co., Ltd.
- Inventors: Kazutoh Takesako; Hideharu Saito; Ikunoshin Kato
- Web page: https://patentgrep.com/patent/US6294581B1

## CPC

- A61K 31/16: Amides, e.g. hydroxamic acids
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The production of IgA is selectively inhibited by orally administering 15-deoxyspergualin or pharmacologically acceptable salts thereof, thus preventing and treating IgA-associated immunological diseases such as IgA nephropathy.

## Claims

### Claim 1

A method for selectively suppressing IgA production in a human or an animal, characterized in that the method comprises orally administering 15-deoxyspergualin or a pharmacologically acceptable salt thereof to a human or an animal in need of selective suppression of IgA production.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said human or animal is one suffering from IgA nephropathy.

### Claim 3 (depends on 1)

The method according to claim 1 wherein said 15-deoxyspergualin or pharmaceutically acceptable salt thereof is administered in an amount sufficient to suppress IgA production without significant suppression of IgC production and/or delayed hypersensitivity.